Hydrochlorothiazide Biogaran (Hydrochlorothiazide)

Hydrochlorothiazide Biogaran is commonly prescribed to address conditions where excess fluid accumulation or elevated blood pressure requires pharmacologic intervention.

• Hypertension (high blood pressure) management, often as part of combination therapy.
• Edema associated with congestive heart failure, liver cirrhosis, or renal disease.
• Reduction of peripheral and pulmonary fluid overload in patients with chronic heart conditions.
• Adjunctive treatment to enhance the effectiveness of other antihypertensive agents.
• Prevention of fluid retention after certain surgical procedures.
• Management of mild to moderate hypertension in patients who respond to thiazide diuretics.

• Hydrochlorothiazide acts by inhibiting the sodium‑chloride symporter located in the distal convoluted tubule of the nephron. Blocking this transporter reduces reabsorption of sodium and chloride, which creates an osmotic gradient that promotes the excretion of sodium, chloride, and water. The resulting natriuresis and diuresis lower extracellular fluid volume, contributing to decreased blood pressure and reduced tissue edema and helps to restore electrolyte balance.

Like other thiazide diuretics, Hydrochlorothiazide Biogaran may cause a range of adverse reactions, most of which are mild and transient, while a few can be serious and require medical attention.

Common

• Increased frequency of urination, especially during the first weeks of therapy.
• Low blood potassium (hypokalemia) leading to muscle cramps or weakness.
• Mild elevation of blood glucose levels in susceptible individuals.
• Slight rise in serum uric acid that may precipitate gout flares.
• Dizziness or light‑headedness due to volume depletion.
• Headache that may accompany fluid shifts.

Serious

• Severe electrolyte disturbances such as hyponatremia or hypercalcemia.
• Acute kidney injury manifested by sudden rise in creatinine.
• Allergic reactions including rash, pruritus, or angioedema.
• Pancreatitis presenting with abdominal pain and elevated enzymes.
• Severe hypotension leading to fainting.

Before initiating Hydrochlorothiazide Biogaran, clinicians should evaluate patient history and laboratory values to identify conditions that may increase the risk of adverse outcomes.

• Assess renal function; avoid use in severe renal impairment.
• Monitor electrolytes, especially potassium, sodium, and calcium, during treatment.
• Use cautiously in patients with a history of gout or hyperuricemia.
• Evaluate blood glucose control in diabetic patients, as thiazides can raise glucose levels.
• Consider the potential for hypotension in individuals on concurrent antihypertensive agents.
• Review any known hypersensitivity to thiazide diuretics or sulfonamide compounds.
• Advise pregnant or breastfeeding women that safety has not been established.

Hydrochlorothiazide Biogaran can alter the pharmacokinetics or pharmacodynamics of several medicines; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Concomitant use with lithium, which may increase lithium toxicity.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can blunt diuretic effect and impair renal function.
• Co‑administration with ACE inhibitors or ARBs in patients prone to hyperkalemia.

Use with caution

• Antidiabetic agents, as thiazides may raise blood glucose and require dose adjustment.
• Cardiac glycosides (e.g., digoxin) because electrolyte shifts can predispose to toxicity.
• Corticosteroids, which can enhance sodium loss and potassium depletion.
• Anticoagulants, where volume changes may affect drug concentration.